March 15th 2023
Factors including age, gender, and facility type may influence the likelihood of pain specialist referrals for lung cancer, suggesting a need for multidisciplinary pain management in this patient population.
February 22nd 2023
February 13th 2023
Patients With Pretreated SCLC Have Improved Outcomes When Apatinib is Added to Chemo
January 30th 2021Updated data from a phase 2 trial of apatinib added to single-agent chemotherapy for small cell lung cancer in patients with prior treatments indicate a good efficacy and safety for the combination.
CASPIAN Update Supports Use of Durvalumab Plus Platinum-Etoposide in Frontline ES-SCLC
January 20th 2021The ongoing phase 3 CASPIAN trial evaluating the use of intravenous durvalumab, with or without tremelimumab, added to platinum–etoposide for the first-line treatment of extensive-stage small cell lung cancer demonstrated improved overall survival versus chemotherapy alone.
Bristol Myers Squibb Withdraws Nivolumab Indication for Treatment of SCLC
January 4th 2021Nivolumab was previously granted accelerated approval by the FDA for the treatment of patients with small cell lung cancer (SCLC) whose disease had progressed after platinum-based chemotherapy and at least 1 other line of therapy, but phase 3 trial results led to a decision to withdraw the indication.
Phase 3 ATLANTIS Study Fails to Meet Primary End Point of OS for Patients with SCLC
December 3rd 2020The study evaluated lurbinectedin (Zepzelca) in combination with doxorubicin versus physician's choice of topotecan or cyclophosphamide/doxorubicin/vincristine for adult patients with small cell lung cancer whose disease progressed following 1 prior platinum-containing line of therapy.
Trilaciclib Reduces Need for Supportive Care Interventions from Chemo-Induced AEs in ES-SCLC
October 21st 2020Treatment with trilaciclib prior to chemotherapy was found to significantly reduce the need for supportive care interventions in the management of severe neutropenia and grade 3/4 anemia induced by chemotherapy in patients with extensive-stage small cell lung cancer, compared with placebo.